




72.22

66.67

61.11

52.78

47.22

41.67

36.11

33.33

30.56

27.78

25.00

22.22

19.44

16.67

13.89

12.78

11.67

10.56

9.44

8.16

7.22

6.67

6.11

5.28

4.72

4.17

3.61

3.33

3.06

2.78

2.50

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

LESS

| ANNUAL - DEC END    | 2015   | 2016  | 2017   | 2018   | 2019   | 2020  | 2021  | 2022   | 2023   | 2024 Estimate               | 2025 Estimate     |                   |     |     |
|---------------------|--------|-------|--------|--------|--------|-------|-------|--------|--------|-----------------------------|-------------------|-------------------|-----|-----|
| EPS CHF             | 4.91   | 5.31  | 10.42  | 7.51   | 10.20  | 11.68 | 39.65 | 16.37  | 8.88   | 13.68                       | 16.68             |                   |     |     |
| CASH FLOW/SHR CHF   | 13.13  | 13.21 | 12.49  | 14.51  | 13.21  | 15.21 | 16.38 | 13.97  | 19.26  | 13.97                       | 19.26             |                   |     |     |
| PRETAX MARGIN %     | 9%     | 9%    | 12%    | 15%    | 17%    | 18%   | 15%   | 23%    | 12%    | 2022-24 -33% (58 Stability) | 2025 Estimate 15% |                   |     |     |
| RETURN ON EQUITY %  | 13%    | 13%   | 16%    | 11%    | 10%    | 11%   | 8%    | 12%    | 7%     | 2020-24 6% (71 Stability)   | 2025 Estimate 11% |                   |     |     |
| SALES % CHANGE      | 4%     | 9%    | 10%    | 22%    | -24%   | 7%    | 20%   | 15%    | 8%     | COMP RATING 79              | SMR RATING C      |                   |     |     |
| SALES (MIL) CHF     | 3,803  | 4,132 | 4,548  | 5,542  | 4,207  | 4,508 | 5,409 | 6,223  | 6,717  | INV T/O 2.9x 59             |                   |                   |     |     |
| WEEKLY              | Jun 28 | Jul 5 | Jul 12 | Jul 19 | Jul 26 | Aug 2 | Aug 9 | Aug 16 | Aug 20 | DEBT %                      | 2021-23           | 26%               | 18% | 31% |
| DATAGRAPH RATING    | 48     | 51    | 52     | 56     | 62     | 63    | 63    | 62     | 62     | TAX RATE                    | 2021-23           | 11%               | 16% | 17% |
| AVG DAILY VOL (000) | 167    | 156   | 153    | 139    | 155    | 157   | 155   | 146    | 147    | BACKLOG                     | 2021-23           |                   |     |     |
| UP/DOWN VOLUME      | 0.7    | 0.7   | 0.9    | 0.7    | 1.2    | 1.1   | 1.1   | 1.3    | 1.3    | R & D                       | 1.60%             | BK VAL 4.27x '23  |     |     |
| ACCUM/DIST RATING   | -31    | -20   | -8     | -13    | 27     | 12    | -2    | 7      | 7      | DIV CHF                     | 4.00 (0.7%)       | DIV GR RT+7% (5)  |     |     |
| RELATIVE STRENGTH   | 50     | 63    | 69     | 90     | 94     | 93    | 96    | 94     | 95     | BETA                        | 1.37(17.00)       | ALPHA 0.03 (0.01) |     |     |
| GROUP RANK          | 12     | 9     | 10     | 8      | 8      | 3     | 4     | 4      | 4      | 2023 EMPLOYEES              | 18,000            | (3%)              |     |     |

PANARAY®

2024 WILLIAM O'NEIL & CO. INC.

Lonza Group (LONN.CH)

Weekly as of TUE 20 August 2024